Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Muchtar E, Gatt ME, Rouvio O, Ganzel C, Chubar E, Suriu C, Tadmor T, Shevetz O, Lavi N, Shochat T, Cohen YC, Avivi I, Raanani P, Magen H. Muchtar E, et al. Among authors: avivi i. Br J Haematol. 2016 Jan;172(1):89-96. doi: 10.1111/bjh.13799. Epub 2015 Nov 16. Br J Haematol. 2016. PMID: 26567759 Free article.
Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy.
Beyar-Katz O, Magidey K, Reiner-Benaim A, Barak N, Avivi I, Cohen Y, Timaner M, Avraham S, Hayun M, Lavi N, Bersudsky M, Voronov E, Apte RN, Shaked Y. Beyar-Katz O, et al. Among authors: avivi i. Mol Cancer Res. 2019 Nov;17(11):2331-2340. doi: 10.1158/1541-7786.MCR-19-0487. Epub 2019 Aug 13. Mol Cancer Res. 2019. PMID: 31409628 Free article.
Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study.
Luttwak E, Gatt ME, Lebel E, Lavi N, Tadmor T, Natalia K, Benyamini N, Horowitz N, Geva M, Suriu C, Avivi I, Trestman S, Mittelman M, Rouvio O, Cohen YC. Luttwak E, et al. Among authors: avivi i. Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e850-e857. doi: 10.1016/j.clml.2020.06.002. Epub 2020 Jun 11. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32624446
Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study.
Ram R, Amit O, Perry C, Herishanu Y, Avivi I, Sarid N, Apel A, Preis M, Aviv A, Shapira S, Shragai T, Joffe E, Shargian L, Herzog-Tsarfati K, Eylati N, Acria L, Fridberg G, Gold R, Glait-Santar C, Kay S, Gal-Rabinovich K, Rosenberg D, Setter-Marco N, Beyar-Katz O. Ram R, et al. Among authors: avivi i. Transplant Cell Ther. 2024 Dec;30(12):1178-1188. doi: 10.1016/j.jtct.2024.09.024. Epub 2024 Oct 11. Transplant Cell Ther. 2024. PMID: 39396632 Clinical Trial.
The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma.
Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H, Tiomkin L, Ribakovsky L, Riback Y, Ramati Y, Aviel S, Galun E, Shaw HL, Eizenberg O, Hardan I, Shimoni A, Nagler A. Peled A, et al. Among authors: avivi i. Clin Cancer Res. 2014 Jan 15;20(2):469-79. doi: 10.1158/1078-0432.CCR-13-1302. Epub 2013 Nov 18. Clin Cancer Res. 2014. PMID: 24246358 Clinical Trial.
256 results